Adicet bio announces poster presentation at the upcoming 2023 molecular targets and cancer therapeutics conference

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for cancer, today announced a poster presentation at the upcoming 2023 international conference on molecular targets and cancer therapeutics hosted by the american association for cancer research, the national cancer institute, and the european organisation for research and treatment of cancer to be held in bos.
ACET Ratings Summary
ACET Quant Ranking